Alphamab Oncology
Alphamab Oncology's Climate Target Data Preview
As of 2024, Alphamab Oncology has disclosed 1 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 1 intensity-based target, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into Alphamab Oncology ’s climate strategy, ambition level, and alignment with global decarbonization goals.
| Target Type | Scope of Target | Unit | Target | Target Year |
|---|---|---|---|---|
Intensity-based Target | Scope 1 - Total, Scope 2 - Total | Metric Tonnes of CO2 equivalent (mtCO2e) per Renminbi/Chinese Yuan (RMB) of Fixed Assets | Copy restricted. Please purchase to unlock this data.  a | 2027 |
Verified Sources Behind Alphamab Oncology’s Climate Targets Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Alphamab Oncology’s data sources below and access millions more through our Disclosure Search.
Insights into Alphamab Oncology's Greenhouse Gas Emissions Pathways
As of 2024, Alphamab Oncology has set greenhouse gas (GHG) emissions reduction targets that cover its operational emissions (Scope 1 and 2), but not its value chain emissions (Scope 3). This means its reduction efforts currently focus on direct and purchased energy emissions. a
Does Alphamab Oncology have a target to reduce the emissions from its operations?
As of 2024, Alphamab Oncology has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources. a
Alphamab Oncology's most ambitious operational target is to reduce these emissions by 15% by 2027, compared to a baseline of 0 Metric Tonnes of CO2 equivalent (mtCO2e) per Renminbi/Chinese Yuan (RMB) of Fixed Assets in 2024. a